| Basics |
Summit Therapeutics Inc. Common Stock
Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.
|
| IPO Date: |
April 1, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$13.63B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.28 | 3.81%
|
| Avg Daily Range (30 D): |
$0.41 | 2.28%
|
| Avg Daily Range (90 D): |
$0.58 | 2.69%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.96M |
| Avg Daily Volume (30 D): |
2.21M |
| Avg Daily Volume (90 D): |
3.07M |
| Trade Size |
| Avg Trade Size (Sh.): |
138 |
| Avg Trade Size (Sh.) (30 D): |
78 |
| Avg Trade Size (Sh.) (90 D): |
91 |
| Institutional Trades |
| Total Inst.Trades: |
1,326 |
| Avg Inst. Trade: |
$3.2M |
| Avg Inst. Trade (30 D): |
$3.87M |
| Avg Inst. Trade (90 D): |
$4.9M |
| Avg Inst. Trade Volume: |
.21M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$5.48M |
| Avg Closing Trade (30 D): |
$4.93M |
| Avg Closing Trade (90 D): |
$7.41M |
| Avg Closing Volume: |
382.03K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-1.25
|
$-.31
|
$-.76
|
|
Diluted EPS
|
$-1.25
|
$-.31
|
$-.76
|
|
Revenue
|
$
|
$
|
$
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -921.62M
|
$ -231.79M
|
$ -565.71M
|
|
Operating Income / Loss
|
$
|
$
|
$
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 144.76M
|
$ -59.34M
|
$ 86.29M
|
|
PE Ratio
|
|
|
|
|
|
|
